GlassScriptPhysician profile
Miguel Sadovnik
NPI 1366490351
$7,252.85
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,176 · 2020: $365 · 2021: $1,451 · 2022: $1,668 · 2023: $1,465 · 2024: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,476.73 | 2019-2024 | Ubrelvy, Qulipta, Viberzi |
| Amgen INC. | $690.18 | 2019-2023 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $573.13 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $561.96 | 2021-2023 | Jardiance, Trulicity, Mounjaro |
| Esperion Therapeutics, INC. | $462.20 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $375.28 | 2019-2023 | Farxiga, Breztri |
| Amarin Pharma, INC. | $370.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.23 | 2019-2023 | Synjardy, Tradjenta, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $286.32 | 2020-2023 | |
| Allergan, INC. | $220.14 | 2019-2020 | |
| Astellas Pharma US INC | $215.11 | 2019-2021 | |
| Pfizer INC. | $214.97 | 2019-2022 | |
| Tactile Systems Technology INC | $144.89 | 2019-2020 | |
| Abbott Laboratories | $139.74 | 2021 | |
| Boston Scientific Corporation | $130.43 | 2023 | Advantage System |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Sadovnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.